Silence Therapeutics plc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was GBP 2.8 million compared to GBP 3.37 million a year ago. Net loss was GBP 8.25 million compared to GBP 7.1 million a year ago. Basic loss per share from continuing operations was GBP 0.222 compared to GBP 0.216 a year ago.
For the nine months, sales was GBP 23.28 million compared to GBP 12.74 million a year ago. Net loss was GBP 28.86 million compared to GBP 26.73 million a year ago. Basic loss per share from continuing operations was GBP 0.792 compared to GBP 0.864 a year ago.